Nektar Therapeutics Files 8-K on Asset Acquisition/Disposition
Ticker: NKTR · Form: 8-K · Filed: Dec 2, 2024 · CIK: 906709
Sentiment: neutral
Topics: acquisition, disposition, corporate-action
TL;DR
Nektar Therapeutics just filed an 8-K for asset acquisition/disposition - big move incoming.
AI Summary
Nektar Therapeutics filed an 8-K on December 2, 2024, reporting the completion of an acquisition or disposition of assets. The filing also includes financial statements and exhibits related to this event. The company is incorporated in Delaware and headquartered in San Francisco, California.
Why It Matters
This filing indicates a significant corporate action by Nektar Therapeutics, potentially impacting its business operations, financial structure, and future strategic direction.
Risk Assessment
Risk Level: medium — Acquisitions or dispositions of assets can significantly alter a company's financial health and strategic focus, introducing both opportunities and risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Francisco, California (location) — Principal Executive Offices
- December 2, 2024 (date) — Date of earliest event reported
FAQ
What specific assets were acquired or disposed of by Nektar Therapeutics?
The filing does not specify the exact assets involved in the acquisition or disposition, only that such an event has occurred.
When did the reported event of asset acquisition or disposition take place?
The earliest event reported in the 8-K filing occurred on December 2, 2024.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is Nektar Therapeutics' IRS Employer Identification Number?
Nektar Therapeutics' IRS Employer Identification Number is 94-3134940.
What is the SEC file number for Nektar Therapeutics?
The SEC file number for Nektar Therapeutics is 000-24006.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-12-02 09:24:44
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0222533-8k_nektar.htm (8-K) — 22KB
- 0001213900-24-104240.txt ( ) — 189KB
- nktr-20241202.xsd (EX-101.SCH) — 3KB
- nktr-20241202_lab.xml (EX-101.LAB) — 33KB
- nktr-20241202_pre.xml (EX-101.PRE) — 22KB
- ea0222533-8k_nektar_htm.xml (XML) — 3KB
01. Completion of Acquisition or
Item 2.01. Completion of Acquisition or Disposition of Assets. On December 2, 2024, Nektar Therapeutics, a Delaware corporation (" Nektar "), completed its previously announced disposition to an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners, a Delaware limited liability company (said affiliate, " Purchaser "), of Nektar's manufacturing facility located in Huntsville, Alabama and certain other manufacturing assets related thereto, as well as Purchaser's assumption of certain related liabilities (collectively, the " Transactions "). The foregoing description of the Transactions does not purport to be complete, and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, dated as of November 1, 2024, entered into between Nektar and Purchaser, which was filed as Exhibit 1.1 to Nektar's Current Report on Form 8-K filed on November 4, 2024, and is hereby incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: December 2, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2